A5019330246- CAR-T cell therapy research
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Fungal Infections and Studies
- Antifungal resistance and susceptibility
- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- GDF15 and Related Biomarkers
- Immunodeficiency and Autoimmune Disorders
- Platelet Disorders and Treatments
- Vascular Tumors and Angiosarcomas
- Hemophilia Treatment and Research
- Mesenchymal stem cell research
- Erythrocyte Function and Pathophysiology
- COVID-19 and Mental Health
- Acute Myeloid Leukemia Research
- Vaccine Coverage and Hesitancy
- Disaster Response and Management
- CNS Lymphoma Diagnosis and Treatment
- Cardiac Fibrosis and Remodeling
- Cancer-related gene regulation
- Infectious Diseases and Mycology
- Corneal Surgery and Treatments
- Healthcare professionals’ stress and burnout
- Skin and Cellular Biology Research
Aristotle University of Thessaloniki
2021-2025
Hippocration General Hospital
2024-2025
Research Network (United States)
2024
Primary HealthCare
2024
Primary Health Care
2024
401 General Military Hospital of Athens
2017
Introduction Bystander hemolysis occurs when antigen-negative red blood cells (RBCs) are lysed by the complement system. Many clinical entities including passenger lymphocyte syndrome, hyperhemolysis following transfusion, and paroxysmal nocturnal hemoglobinuria complicated bystander hemolysis.
(1) Background: Autologous, allogeneic hematopoietic cell transplantation (HCT) and other cellular therapies, including CAR T gene therapy, constitute a cornerstone in the management of various benign malignant hematological disorders. Invasive fungal infections (IFD) remain significant cause morbidity mortality HCT recipients. Therefore, we investigated prevalence risk factors IFD following therapies an era novel antifungal prophylaxis. (2) Methods: In this study, retrospectively enrolled...
This study evaluates the health-related quality of life (HRQoL) among patients with hemophilia A currently undergoing prophylactic treatment at Hemophilia Center Northern Greece. Using Haem-A-QoL questionnaire, we assessed various HRQoL dimensions in a cohort 29 adult male patients, analyzing impact age, disease severity, and regimens. The results revealed that younger (18–30 years old) exhibited significantly better overall scores (total score 25.36) compared to older age groups (37.81 for...
Background/Objectives: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis or obstetric complications and the laboratory detection of antiphospholipid antibodies. Although vascular main manifestation disease, other rarer have also been described. Avascular necrosis (AN) considered rare APS. The aim our case series to study patients with APS AN. Methods: A retrospective was performed on 80 diagnosed Results: AN observed in 3 out femoral head all cases....
Background: In this prospective study, the prognostic role of ADAMTS13 activity and von Willebrand (VWF) antigen (VWF: Ag) levels in ischemic stroke outcomes was investigated. Methods: Patients diagnosed with acute were prospectively enrolled while samples for VWF: Ag level measurements collected upon their admission to our unit. The National Institutes Health Stroke Scale (NIHSS) score estimated at discharge. modified Rankin scale neurologic disability (Rankin) based on patient's history...
(1) Background: Antiphospholipid syndrome (APS) is associated with thrombotic events and the laboratory identification of antiphospholipid antibodies (aPL), in which lupus anticoagulant (LA), anticardiolipin (aCL), anti-β2 glycoprotein I are included. The aim current retrospective study to examine clinical characteristics risk factors ischemic stroke as a manifestation APS. (2) Methods: Adult patients diagnosed APS between 1 January 2009 June 2024 were retrospectively enrolled this study....
Immunotherapy with chimeric antigen receptor T (CAR-T) cell therapies has brought substantial improvement in clinical outcomes patients relapsed/refractory B neoplasms. However, complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) limit the therapeutic efficacy of this treatment approach. ICANS can have a broad range manifestations, while various scoring systems been developed for its grading. Cognitive decline is prevalent CAR-T...
Endothelial injury indices, such as Activation and Stress Index (EASIX), modified EASIX (m-EASIX), simplified (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), soluble C5b-9 (sC5b-9) described markers of endothelial post-hematopoietic stem transplantation. In the current study, we examined whether suPAR, GDF-15,...
Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) immunotherapy are widely used for the management of hematological malignancies. HSCT can be complicated by endothelial injury syndromes, such as HSCT-thrombotic microangiopathy (HSCT-TMA) sinusoidal obstructive syndrome/ veno-occlusive disease (SOS/VOD), which life-threatening. Moreover, venous thromboembolic events (VTEs) common in recipients due to injury, use central catheters, prolonged...
Cardiovascular disease remains the main cause of mortality in 21st century. Hypertension, vessel atherosclerosis, and familial hypercholesterolemia (FH) are responsible for increased morbidity patients. Therapies cardiovascular based on drug treatment options, but era precision medicine, personalized treatments being developed. Studies have shown that these conditions a strong genetic background, creating an opportunity implementation gene therapy diseases. Currently, is not widely used...
Despite novel biological agents, steroid-dependent or -refractory graft-versus-host disease (GvHD) remains a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT). Extracorporeal photopheresis (ECP) is an alternative, non-immunosuppressive treatment for patients with acute (aGvHD) chronic (cGvHD) GvHD. The aim this study was to investigate the safety and efficacy ECP in GvHD;